Document is current
Any future updates will be listed below
-
Authors
Rossiello, Francesca https://orcid.org/0000-0002-6240-9907
Cicio, Giada https://orcid.org/0000-0002-4121-5679
Sepe, Sara https://orcid.org/0000-0002-9884-9189
Mancheno-Ferris, Alexandra https://orcid.org/0000-0002-2689-8483
Cancila, Valeria
Castellini, Arianna https://orcid.org/0009-0006-7410-3231
Rey, Federica https://orcid.org/0000-0001-7944-3143
Bertolazzi, Giorgio
Oppezzo, Alessia
Marinelli, Eugenia
Cabrini, Matteo
di Lillo, Alessia
Tavella, Sara
Rosso, Ilaria
Buffa, Francesca M
Tripodo, Claudio
d’Adda di Fagagna, Fabrizio https://orcid.org/0000-0002-9603-5966
-
Funding
Funding for this research was provided by:
EC | European Research Council (835103)
EC | European Research Council (101113229)
Fondazione AIRC per la ricerca sul cancro ETS (30471)
Fondazione AIRC per la ricerca sul cancro ETS (21762)
Fondazione AIRC per la ricerca sul cancro ETS (21091)
Fondazione AIRC per la ricerca sul cancro ETS (28978)
Fondazione AIRC per la ricerca sul cancro ETS (28154)
Fondazione Telethon (GMR23T2007)
Progetti di Ricerca di Interesse Nazionale (2020CXFL4T)
Progetti di Ricerca di Interesse Nazionale (2022R7LH5T)
Fondazione Regionale per la Ricerca Biomedica (EJPRD19-206 PROGERIA)
Next Generation EU, in the context of the National Recovery and Resilience Plan, Investment PE8 (Project Age-It)
Investment CN3 National Center for Gene Therapy and Drugs based on RNA Technology
- License Information
-
More Information
Article History
Received: 20 May 2025
Revised: 16 July 2026
Accepted: 23 July 2026
First Online: 12 August 2026
Disclosure and competing interests statement
: Fd’AdF and FR are inventors on the patent applications for RNA products and uses thereof (PCT/EP2013/ 059753); Therapeutic oligonucleotides (PCT/EP2016/068162). Fd’AdF is a shareholder of TAG Therapeutics. AdL is an employer of Thermo Fisher Scientific. The remaining authors declare no competing interests.
